GET DAILY SIGNALSElicio Therapeutics ELTX Narrows Q3 Loss While Refining Its KRAS Strategy
Key Takeaways
- Elicio Therapeutics reported a third-quarter 2026 net loss of $8.0 million, or $0.30 per share, narrowing from $10.1 million, or $0.60 per share, in the same period a year earlier.
- Reported loss per share of $0.30 beat consensus estimates of roughly $0.43 to $0.44.
- Research and development (R&D) expense declined 3% year over year to $4.9 million, while general and administrative (G&A) expense rose 18.5% to $3.6 million.
- Cash and cash equivalents totaled $30.9 million as of September 30, 2026, which the company expects to fund operations into the second quarter of 2027.
- The Phase 2 AMPLIFY-7P trial of camupepimut missed its primary endpoint, but pre-specified subgroup analyses are guiding a refined Phase 3 strategy in adjuvant pancreatic cancer.
Earnings Context and Clinical Background
Elicio Therapeutics is a clinical-stage biotechnology company focused on immunotherapies for KRAS-driven cancers. Its lead candidate, camupepimut (ELI-002 7P), targets mutant KRAS-positive pancreatic ductal adenocarcinoma. As a pre-revenue firm, its quarterly updates are judged primarily on clinical progress, spending discipline, and cash runway rather than revenue. This third-quarter 2026 release came shortly after the Phase 2 AMPLIFY-7P study missed its primary endpoint, so the report drew more attention for management’s forward framing than for the headline loss itself. I checked sector peers using Tickeron’s AI Screener to see how ELTX compares on key financial metrics.
Quarterly Results in Detail
For the third quarter of 2026, Elicio Therapeutics posted a net loss of $8.0 million versus $10.1 million a year earlier, a reduction of about 21%. Loss per share came in at $0.30 compared with $0.60 in the prior-year quarter and beat the consensus estimate of roughly $0.43 to $0.44 per share.
R&D expense fell 3% year over year to $4.9 million, mainly due to lower clinical-trial costs as patients moved into follow-up for the Phase 2 camupepimut study. G&A expense rose 18.5% to $3.6 million, pushing total operating expenses up 5.1% to $8.5 million.
Over the first nine months of 2026, the net loss narrowed to $28.0 million from $31.9 million. Cash and cash equivalents reached $30.9 million at September 30, 2026, up from $18.6 million at the end of 2025, helped by $4.3 million raised via the at-the-market program in the third quarter and roughly $13.6 million from a July 2026 registered direct offering.
Market Reaction and Sentiment
ELTX shares have remained under pressure since the Phase 2 miss on disease-free survival, trading well below the 52-week high and in the low single digits around the earnings release. The narrower-than-expected loss offered only modest support, with investor focus staying on the clinical story. Analysts have trimmed some price targets while keeping Buy ratings, reflecting caution around the revised development plan and the need to conserve capital ahead of upcoming milestones.
Forward Path and Items to Watch
Investors will want to see how Elicio Therapeutics converts its subgroup findings into a registrational strategy. Although AMPLIFY-7P missed the primary endpoint, management pointed to pre-specified analyses that favor camupepimut in select patient groups and plans to use those data to shape a targeted Phase 3 program in adjuvant pancreatic ductal adenocarcinoma.
A near-term catalyst is the planned Phase 1 combination trial of camupepimut with daraxonrasib, with or without nivolumab, in metastatic disease, slated to begin in the fourth quarter of 2026. Additional data readouts and presentations will also draw attention.
Financially, the key variable remains capital. With $30.9 million in cash expected to last only into the second quarter of 2027, further financing will likely be required. Cost control in R&D and any future share issuance stay important considerations for shareholders.
AI Tools Supporting My Analysis
I frequently use Tickeron’s AI Screener to quickly filter biotech names by fundamentals, technical patterns, and performance metrics. It helps me compare ELTX against peers and spot potential trade ideas without spending hours on manual screens. The tool serves as a useful complement to fundamental research on clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ELTX sees its Stochastic Oscillator ascending out of oversold territory
On November 09, 2026, the Stochastic Oscillator for ELTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 77 instances where the indicator left the oversold zone. In 70 of the 77 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ELTX's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ELTX just turned positive on November 09, 2026. Looking at past instances where ELTX's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Following a +17.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELTX advanced for three days, in 202 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ELTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELTX as a result. In 98 of 116 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ELTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.000) is normal, around the industry mean (3.498). P/E Ratio (-0.702) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ELTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement